文献速递临床试验与 GCP

胃癌胃切除术中保留大网膜与完全大网膜切除术比较(OMEGA试验):一项随机对照试验的研究方案

Omentum preservation versus complete omentectomy in gastrectomy for gastric cancer (OMEGA trial): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2024-09-04

OMEGA是一项随机对照、开放、平行、非劣效性、多中心试验,纳入可手术(ASA<4)且可切除(≦cT4aN3bM0)的原发性胃癌患者,1:1随机接受胃(次)全切除加胃网膜血管远端大网膜保留或完全大网膜切除,目标样本量654例,主要终点为3年总生存率的非劣效性。

要点

  • OMEGA试验比较胃癌胃切除术中保留大网膜与完全大网膜切除,主要终点为3年总生存率非劣效性。
  • 纳入标准为可手术(ASA<4)且可切除(≦cT4aN3bM0)的原发性胃癌患者。
  • 目标样本量654例,按1:1随机分组,非劣效性基于意向性治疗和符合方案分析结果判定。

核心结论

  • OMEGA试验旨在探究胃癌胃切除术中保留大网膜在3年总生存率方面是否非劣效于完全大网膜切除术。
  • OMEGA试验将阐明常规完全大网膜切除术是否可被省略,从而可能减少过度治疗。

研究设计与样本

  • OMEGA是一项随机对照、开放、平行、非劣效性、多中心试验。
  • 纳入可手术(ASA<4)且可切除(≦cT4aN3bM0)的原发性胃癌患者,按1:1随机分配至胃(次)全切除加胃网膜血管远端大网膜保留组或完全大网膜切除组。
  • 在80%把握度下,目标样本量为654例患者。

主要发现

  • 主要目的为研究胃癌胃切除术中保留大网膜在3年总生存率方面是否非劣效于完全大网膜切除术。
  • 次要终点包括术中及术后结局,如失血量、手术时间、住院时间、再入院率、生活质量、无病生存期和成本效益。
  • 非劣效性基于意向性治疗和符合方案分析两项结果判定。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Potentially curative therapy for locally advanced gastric cancer consists of gastrectomy, usually in combination with perioperative chemotherapy. An oncological resection includes a radical (R0) gastrectomy and modified D2 lymphadenectomy; generally, a total omentectomy is also performed, to ensure the removal of possible microscopic disease. However, the omentum functions as a regulator of regional immune responses to prevent infections and prevents adhesions which could lead to bowel obstructions. Evidence supporting a survival benefit of routine complete omentectomy during gastrectomy is lacking. METHODS: OMEGA is a randomized controlled, open, parallel, non-inferiority, multicenter trial. Eligible patients are operable (ASA < 4) and have resectable (≦ cT4aN3bM0) primary gastric cancer. Patients will be 1:1 randomized between (sub)total gastrectomy with omentum preservation distal of the gastroepiploic vessels versus complete omentectomy. For a power of 80%, the target sample size is 654 patients. The primary objective is to investigate whether omentum preservation in gastrectomy for cancer is non-inferior to complete omentectomy in terms of 3-year overall survival. Secondary endpoints include intra- and postoperative outcomes, such as blood loss, operative time, hospital stay, readmission rate, quality of life, disease-free survival, and cost-effectiveness. DISCUSSION: The OMEGA trial investigates if omentum preservation during gastrectomy for gastric cancer is non-inferior to complete omentectomy in terms of 3-year overall survival, with non-inferiority being determined based on results from both the intention-to-treat and the per-protocol analyses. The OMEGA trial will elucidate whether routine complete omentectomy could be omitted, potentially reducing overtreatment. TRIAL REGISTRATION: ClinicalTrials.gov NCT05180864. Registered on 6th January 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Keywani K, Eshuis WJ, Borgstein ABJ, et al. Omentum preservation versus complete omentectomy in gastrectomy for gastric cancer (OMEGA trial): study protocol for a randomized controlled trial. Trials. 2024. PMID: 39232781. doi:10.1186/s13063-024-08396-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。